BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.960
+0.090 (4.81%)
Apr 28, 2025, 4:00 PM EDT - Market closed

Company Description

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.

The company develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders; and its immune-oncology candidate, BXCL 701, which is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

It also develops IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults; BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia.

BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics, Inc.
BioXcel Therapeutics logo
Country United States
Founded 2017
IPO Date Mar 8, 2018
Industry Biotechnology
Sector Healthcare
Employees 37
CEO Vimal Mehta

Contact Details

Address:
555 Long Wharf Drive, 12th Floor
New Haven, Connecticut 06511
United States
Phone 475 238 6837
Website bioxceltherapeutics.com

Stock Details

Ticker Symbol BTAI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001720893
CUSIP Number 09075P105
ISIN Number US09075P1057
Employer ID 82-1386754
SIC Code 2834

Key Executives

Name Position
Dr. Vimal D. Mehta Ph.D. Founder, Chief Executive Officer, President, and Director
Richard I. Steinhart MBA Senior Vice President and Chief Financial Officer
Javier Rodriguez J.D. Senior Vice President, Chief Legal Officer and Corporate Secretary
Dr. Frank D. Yocca Ph.D. Executive Vice President and Chief Scientific Officer

Latest SEC Filings

Date Type Title
Apr 4, 2025 S-8 Securities to be offered to employees in employee benefit plans
Apr 3, 2025 8-K Current Report
Apr 3, 2025 424B5 Filing
Mar 28, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Mar 21, 2025 8-K Current Report
Mar 21, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Mar 4, 2025 424B5 Filing
Mar 3, 2025 8-K Current Report